Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
出版年份 2012 全文链接
标题
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
作者
关键词
-
出版物
BLOOD
Volume 119, Issue 18, Pages 4133-4141
出版商
American Society of Hematology
发表日期
2012-02-22
DOI
10.1182/blood-2011-12-400044
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- In vivo Inhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy
- (2011) J. C. Lee et al. CANCER RESEARCH
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
- (2011) Sid P. Kerkar et al. JOURNAL OF CLINICAL INVESTIGATION
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Enhanced Sensitivity to IL-2 Signaling Regulates the Clinical Responsiveness of IL-12-Primed CD8+ T Cells in a Melanoma Model
- (2011) D. N. Lisiero et al. JOURNAL OF IMMUNOLOGY
- CARs on Track in the Clinic
- (2011) Donald B Kohn et al. MOLECULAR THERAPY
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- (2010) C. H. J. Lamers et al. BLOOD
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
- Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
- (2010) S. P. Kerkar et al. CANCER RESEARCH
- Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens
- (2010) Xi Zhao et al. MOLECULAR THERAPY
- Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice
- (2009) S. E. James et al. BLOOD
- Interleukin 12 Stimulates IFN- -Mediated Inhibition of Tumor-Induced Regulatory T-Cell Proliferation and Enhances Tumor Clearance
- (2009) X. Cao et al. CANCER RESEARCH
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More